ConductScience.org, home

Paper17520463

Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.

Berends MA and 5 others. J Dermatolog Treat, 2007. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. Papers, record 17520463. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17520463

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
PubMed
Journal
J Dermatolog Treat
PubMed
Year
2007
PubMed
Publication types
Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
0.88
iCite
Revised in PubMed
2019-12-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Berends MAMaartje A M
2Driessen RJRieke J B
3Langewouters AMAnnechien M G
4Boezeman JBJan B
5Van De Kerkhof PCPeter C M
6De Jong EMElke M G J

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Immunoglobulin GMajor topic
Immunologic FactorsMajor topic
PsoriasisMajor topic
Receptors, Tumor Necrosis FactorMajor topic
Adult
Aged
Antibodies, Monoclonal, Humanized
Cohort Studies
Etanercept
Female
Humans
Injections, Subcutaneous
Male
Middle Aged
Prospective Studies
Severity of Illness Index
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
39959643Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.J Inflamm Res2025https://conductscience.org/library/papers/39959643PubMed
34067151Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.Int J Mol Sci2021https://conductscience.org/library/papers/34067151PubMed
31490403Effectiveness comparisons of traditional Chinese medicine for psoriasis: A Bayesian network meta-analysis.Medicine (Baltimore)2019https://conductscience.org/library/papers/31490403PubMed
31027118Effectiveness comparisons of acupuncture for psoriasis: A Bayesian network meta-analysis protocol.Medicine (Baltimore)2019https://conductscience.org/library/papers/31027118PubMed
27895471Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature.Patient Prefer Adherence2016https://conductscience.org/library/papers/27895471PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17520463

GET https://conductscience.org/api/papers/v1/17520463/authors